310 related articles for article (PubMed ID: 30125611)
21. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Burstein HJ; Krilov L; Aragon-Ching JB; Baxter NN; Chiorean EG; Chow WA; De Groot JF; Devine SM; DuBois SG; El-Deiry WS; Epstein AS; Heymach J; Jones JA; Mayer DK; Miksad RA; Pennell NA; Sabel MS; Schilsky RL; Schuchter LM; Tung N; Winkfield KM; Wirth LJ; Dizon DS
J Clin Oncol; 2017 Apr; 35(12):1341-1367. PubMed ID: 28148207
[No Abstract] [Full Text] [Related]
22. Recent advances in biosensor development for the detection of cancer biomarkers.
Jayanthi VSPKSA; Das AB; Saxena U
Biosens Bioelectron; 2017 May; 91():15-23. PubMed ID: 27984706
[TBL] [Abstract][Full Text] [Related]
23. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
24. [Cancer: three eras of personalized medicine].
Jordan B
Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
[TBL] [Abstract][Full Text] [Related]
25. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
26. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?
Morgan G; Aftimos P; Awada A
Curr Opin Oncol; 2016 Sep; 28(5):441-6. PubMed ID: 27428363
[TBL] [Abstract][Full Text] [Related]
27. Current trends and emerging diagnostic techniques for lung cancer.
Prabhakar B; Shende P; Augustine S
Biomed Pharmacother; 2018 Oct; 106():1586-1599. PubMed ID: 30119234
[TBL] [Abstract][Full Text] [Related]
28. Biosensors for cancer markers diagnosis.
Tothill IE
Semin Cell Dev Biol; 2009 Feb; 20(1):55-62. PubMed ID: 19429492
[TBL] [Abstract][Full Text] [Related]
29. Advances in nanoplasmonic biosensors for clinical applications.
Mauriz E; Dey P; Lechuga LM
Analyst; 2019 Dec; 144(24):7105-7129. PubMed ID: 31663527
[TBL] [Abstract][Full Text] [Related]
30. Implantable biosensors and their contribution to the future of precision medicine.
Gray M; Meehan J; Ward C; Langdon SP; Kunkler IH; Murray A; Argyle D
Vet J; 2018 Sep; 239():21-29. PubMed ID: 30197105
[TBL] [Abstract][Full Text] [Related]
31. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
[No Abstract] [Full Text] [Related]
32. Network science in clinical trials: A patient-centered approach.
Manem VSK; Salgado R; Aftimos P; Sotiriou C; Haibe-Kains B
Semin Cancer Biol; 2018 Oct; 52(Pt 2):135-150. PubMed ID: 29278737
[TBL] [Abstract][Full Text] [Related]
33. Emerging trends in biomarker discovery: Ease of prognosis and prediction in cancer.
Sharma AK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):iii-iv. PubMed ID: 29857038
[No Abstract] [Full Text] [Related]
34. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
Walko C; Kiel PJ; Kolesar J
Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
[TBL] [Abstract][Full Text] [Related]
35. Future Clinical Trials: Genetically Driven Trials.
Astsaturov I
Surg Oncol Clin N Am; 2017 Oct; 26(4):791-797. PubMed ID: 28923231
[TBL] [Abstract][Full Text] [Related]
36. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.
Prudkin L; Nuciforo P
Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990
[TBL] [Abstract][Full Text] [Related]
37. Optical biosensors to analyze novel biomarkers in oncology.
Donzella V; Crea F
J Biophotonics; 2011 Jun; 4(6):442-52. PubMed ID: 21567973
[TBL] [Abstract][Full Text] [Related]
38. Immunohisto(cyto)chemistry: an old time classic tool driving modern oncological therapies.
Cooks T; Theodorou SD; Paparouna E; Rizou SV; Myrianthopoulos V; Gorgoulis VG; Pateras IS
Histol Histopathol; 2019 Apr; 34(4):335-352. PubMed ID: 30480312
[TBL] [Abstract][Full Text] [Related]
39. Shifting paradigm of cancer diagnoses in clinically relevant samples based on miniaturized electrochemical nanobiosensors and microfluidic devices.
Mahato K; Kumar A; Maurya PK; Chandra P
Biosens Bioelectron; 2018 Feb; 100():411-428. PubMed ID: 28957706
[TBL] [Abstract][Full Text] [Related]
40. Toward biosensors for the detection of circulating microRNA as a cancer biomarker: an overview of the challenges and successes.
Tavallaie R; De Almeida SR; Gooding JJ
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(4):580-92. PubMed ID: 25529633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
